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Abstract
Background: Mutation, promoter hypermethylation and loss of heterozygosity involving the tumor suppressor gene p16
(CDKN2a/INK4a) have been detected in a wide variety of human cancers, but much less is known concerning the frequency
and spectrum of p16 mutations in premalignant conditions.
Methods and Findings: We have determined the p16 mutation spectrum for a cohort of 304 patients with Barrett’s
esophagus, a premalignant condition that predisposes to the development of esophageal adenocarcinoma. Forty seven
mutations were detected by sequencing of p16 exon 2 in 44 BE patients (14.5%) with a mutation spectrum consistent with
that caused by oxidative damage and chronic inflammation. The percentage of patients with p16 mutations increased with
increasing histologic grade. In addition, samples from 3 out of 19 patients (15.8%) who underwent esophagectomy were
found to have mutations.
Conclusions: The results of this study suggest the environment of the esophagus in BE patients can both generate and
select for clones with p16 mutations.
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Introduction
p16 (CDKN2a/INK4a) (OMIM #600160) is a cyclin depen-
dent kinase inhibitor that regulates cell cycle progression through
the G1/S restriction point by binding to cyclin dependent kinases
4 and 6, preventing phosphorylation of the retinoblastoma protein
[1,2]. Germline mutations in p16 have been associated with
familial melanoma syndromes [3], and somatic alterations in p16
have been detected in a wide variety of cancers [4,5]. These
alterations occur by multiple mechanisms, including mutation, loss
of heterozygosity (LOH) and promoter hypermethylation. Given
its role in modulating cell proliferation, it is not surprising that p16
alterations are one of the most common genetic/epigenetic
alterations in cancer.
Barrett’s esophagus (BE) is a premalignant condition in which the
squamous epithelium that normally lines the esophagus is replaced
with specialized intestinal epithelium as a result of chronic
gastroesophageal reflux [6]. Patients with BE have a 30–40 fold
increased risk of developing esophageal adenocarcinoma (EA), a
cancer that has increased inincidencemorethan 600%over the past
three decades (1972–2002) [7–9]. EA and esophageal squamous cell
carcinoma (SCC) are the two major types of cancer that develop in
the esophagus. In contrast to EA, SCC rates have declined inthe US
over the same time period [9]. Both types of esophageal cancer are
thought to be promoted by environmental exposures (smoking and
alcohol use for SCC, chronic gastroesophageal reflux for EA), but
the molecular pathwaysinvolvedwith neoplasticprogression inthese
two cancers are thought to be different [10]. A number of studies
have examined the involvement of p16 mutations in esophageal
cancer[4,11–15],themajorityofwhichhavefocused primarilyupon
SCC. Less is know concerning the frequency and spectrum of p16
mutationsinEA,andverylittleaboutp16mutationsinBE.Here,we
report p16 mutation detection and characterization in a prospective
cohort study of 304 patients with BE and from 19 patients for which
esophagectomy samples were available. We find p16 mutations can
occur very early during neoplastic progression in BE, and the
spectrum of mutationisconsistent with that ofoxidativedamage that
can be generated as a result of chronic reflux.
Materials and Methods
Patient characteristics and biopsy acquisition
Patients were enrolled in The Seattle Barrett’s Esophagus
Research Program, a dynamic cohort study that began in 1983.
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3809All participants in this study were recruited from this continuing
program of cancer surveillance in which participants undergo
periodic endoscopy with multiple biopsies following a standard
protocol [16]. The study was approved by the Human Subjects
Division of the University of Washington in 1983 and renewed
annually thereafter with reciprocity from the Fred Hutchinson
Cancer Research Center from 1993 to 2001. Since 2001, the study
has been approved annually by the IRB of the FHCRC with
reciprocity from the Human Subjects Division of the University of
Washington. Flow-sorted samples from multiple biopsies of
Barrett’s epithelium were evaluated from 304 patients who at
baseline endoscopy had BE without cancer. Of the 304 patients,
235 were male (77%) and 69 were female (23%). The mean age of
the patients was 62.7 years (range 30.5 to 87.3) (Table 1). This
study was conducted at a specialty research and referral center,
and thus our cohort is considered a high-risk patient population.
Biopsies were acquired at 2-cm intervals throughout the Barrett’s
segment using endoscopic mapping protocols described previously
[16–19]. Normal gastric tissue served as a constitutive control for
each patient. Patients were counseled regarding the risks and
benefits of endoscopic surveillance and informed of potential
alternative therapies, including surgery and endoscopic ablation,
for high-grade dysplasia. Written informed consent for research
use of biopsies and esophagectomy specimens was obtained from
all patients in this study. Samples from 27 patients who had
undergone esophagectomy were also examined for p16 mutation.
Eight of these patients also had samples from a baseline endoscopy
and were removed from analysis of frequency of mutation to
prevent duplication of data.
Histology
Endoscopic biopsies were processed and interpreted for grade of
dysplasia. Mutation at p16 was assessed in biopsies taken at levels
adjacent to those used for histology and patients were classified
according to the maximum histologic grade of dysplasia in any
biopsy, as described previously [16,17,19]. Of the 304 patients, 90
were negative for dysplasia, 95 were indefinite for dysplasia, 58
had low-grade dysplasia range (LGD), and 61 had high-grade
dysplasia (HGD) (Table 1). The maximum histologic grade of the
samples from the esophagectomies ranged from unknown (n=2)
to low-grade/indefinite for dysplasia (1), high-grade dysplasia (8),
up through EA (16). Histologic or p16 mutation data from
previous endoscopies from many of these patients were not
available; because of this, data from the esophagectomy specimens
was analyzed separately from that obtained from endoscopic
biopsies.
Flow Cytometric Sorting and DNA Extraction
Barrett’s epithelial cell populations were purified from endo-
scopic biopsies and esophagectomy samples by means of Ki67/
DNA content flow sorting of diploid G1, 4N, and aneuploid cell
populations on a Coulter Elite ESP cell sorter, as described
previously [20–22]. This process enriches for epithelial cell (BE)
populations and removes underlying genotypically normal stromal
cells, allowing less ambiguous detection and characterization of
mutations.
DNA Sequencing
Evaluation of mutations in exon 2 of the p16 gene was
performed on an aliquot of genomic DNA that had undergone
whole genome amplification (PEP) [23] as previously described
[24]. We sequenced exon 2 of p16 since the vast majority of p16
mutations reported in the literature lie within this exon.
Sequencing was performed using BigDye Terminator cycle
sequencing (Applied Biosystems, Foster City, CA) on an ABI
377 DNA sequencer. Wild type sequences for each patient were
Table 1. Cohort characteristics.
Patients with endoscopic samples Male 235
Female 69
Average age 63 (range 30 to 87)
Average # biopsies per patient 4.4
Diagnosis Mutation frequency
High-grade dysplasia 12/61 (19.7%)
Low-grade/Indefinite 27/153 (17.6%)
Metaplasia 5/90 (5.5%)
All 44/304 (14.5%)
Patients with esophagectomy samples Male 18
Female 1
Average age 67 (range 43 to 93)
Average # biopsies per patient 5.4
Diagnosis Mutation frequency
EA 1/13 (6.25%)
High-grade dysplasia 1/3 (33.3%)
Low-grade/Indefinite 1/1 (100.0%)
Metaplasia 0/0 (NA)
Unknown 0/2 (0.0%)
All 3/19 (15.8%)
doi:10.1371/journal.pone.0003809.t001
p16 Mutations in BE
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confirmed by at least two independent PCR and sequencing
reactions, and in cases of ambiguity, by direct sequencing of
genomic DNA. The mutation sequence for 2 patients have been
previously reported [24,25] and the frequency of p16 mutations,
but not the sequences, for a subset of the patients in this study
(N=107) was reported in a previous publication [24].
LOH status and deletion status
LOH status was determined as described previously [21,26].
The LOH status of the patients in this study has been presented
previously [24,25,27,28], but the associations between LOH and
p16 mutation have not been presented previously. Deletions at the
p16 locus were determined using array CGH of BAC clones in
and around the p16 locus, which are described in detail elsewhere
(Paulson, et al, submitted). LOH was further defined as copy
neutral (loss of one allele, but no change in copy number) or copy
loss LOH (loss of one allele due to deletion of p16 sequence).
Deletion data were available for 105 samples from 65 patients for
analysis of copy neutral and copy loss LOH.
Clonal ordering
The order of genetic events can be determined by comparing
which events are present in biopsies from patients in which both
events are observed [29]. For events A and B, there are 4 possible
relationships: A precedes B, B precedes A, A and B occur together,
or A and B are independent of each other.
Statistical analyses
Assessment of a trend for more p16 mutations in samples from
patients with more advanced histologic diagnoses was performed
using the Cochran-Armitage trend test. Frequencies of p16
mutations in different subgroups were compared using Fischer’s
exact test.
Results
We evaluated 1346 biopsies from 304 patients with BE (average
of 4 per patient, range 1 to 20) having diagnoses ranging from
metaplasia negative for dysplasia to HGD (Table 1). Forty-four of
the 304 patients (14.5%) had a total of 47 mutations in endoscopic
biopsies from the Barrett’s segment (Figure 1). Three patients had
two different p16 mutations that were located in spatially distinct
regions of the Barrett’s segment. No germline mutations were
detected in the constitutive samples. Fewer alterations were found
in patients with metaplasia alone and there was a significant trend
towards a higher frequency of alterations with increasing histologic
grade (p=0.009). The spectrum of these mutations is indicated in
Figure 2 and Table 2. Sixty percent of the mutations occurred at
three sites–bp 172 (R58X), bp 238 (R80X) and bp 247 (H83Y)–
and were all CRT transitions. Transitions at CpG sites (49%) and
insertions/deletion (23%) made up the majority of the observed
mutations. Of the 36 point mutations, 88% (32/36) resulted in
either a conservative amino acid change or no change in the
coding sequence of p14 ARF. Seven patients of the 27 having
samples from esophagectomy specimens had mutations in p16
(Table 3). Some patients (n=8) had samples available both from
baseline endoscopy as well as from an esophagectomy: of these 8
patients, all those that had a p16 mutation present in the
esophagectomy specimen (n=4) had the same mutation(s) present
at baseline endoscopy. Samples from 3 of the remaining 19
esophagectomy samples (15.8%) contained p16 mutations.
Consistent with earlier studies [24,25], clonal cell populations
with p16 mutations were found to have expanded in the Barrett’s
segment. Among patients whose Barrett’s segment length was
$2 cm, p16 mutations extended over an average of 66.4% of the
Barrett’s epithelium, including cases in which the same mutation
was detected in 6 biopsies across 12 cm of esophageal mucosa.
These results are similar to those obtained when using 9p21 LOH
as a measure of clonality, in which clones with the same LOH
patterns were found over an average of 55% of the esophagus, to a
maximum of 100% of a 17 cm segment.
p16 mutation represents one of the two hits required to
inactivate the gene, along with copy neutral LOH, deletion/copy
loss LOH, or promoter hypermethylation; therefore, we examined
the associations between p16 mutation, LOH and deletion in
patients with BE. We found no statistical difference between the
frequency of copy neutral and copy loss LOH (51% vs. 49%,
respectively). However, we found copy neutral LOH was much
more common in samples with a p16 mutation (7/8, 87.5%) than
in samples without a p16 mutation (20/45, 44.4%) (p=0.05), and
that p16 mutation was found in samples with copy neutral LOH
significantly more often than with copy loss LOH (7/27 vs 1/26,
p=0.05). Finally, we examined the order in which p16 mutation
and LOH (either type) occurred in this BE cohort. In 18 evaluable
patients in which both LOH and mutation were found, we found
independent LOH and mutation events in 6 patients, LOH
occurred before mutation in 8 patients and mutation before LOH
in 4 patients, suggesting that when mutation and LOH both
happen, there is no preferential order.
Discussion
Previous studies examining the frequency of p16 mutation in
esophageal cancer have focused primarily upon SCC in surgical
resections, with reported frequencies of mutation ranging from 0%
to 52%, with most studies reporting 15–20% [4,14,30]. We found
15.8% of esophagectomy samples to have p16 mutations, similar
to the frequency in BE patients (14.5%) . Our study provides the
most extensive examination to date of p16 mutations in a
premalignant tissue (BE). p16 mutations were detected at all
histologic grades, indicating they can develop as very early events
in neoplastic progression of BE. Since p16 can be inactivated by
multiple mechanisms, including methylation and LOH, analysis of
cancer risk associated with p16 mutation alone was not possible in
this study. However, we have evaluated a cohort of 138 patients
for whom mutation, LOH and methylation were evaluated and
found no difference in cancer risk between patients with p16
mutation alone vs. methylation or LOH alone (TG Paulson,
unpublished observations). As well, in a prospective study of
multiple variables influencing risk of progression to EA, p16
mutation alone was not found to have significant predictive value
[27]. These findings support the idea that loss of p16 function (and
possibly other genes in the 9p21 chromosomal region), rather than
the mechanism of its inactivation, is the important step in the
development of EA.
Mutations at the p16 codons altered in BE have been observed
in a variety of cancers, including melanoma, bladder, oral SCC
and NSCLC [31]. Two of the three most common mutations
observed in BE, at amino acids 58 and 80 (bp 172 and 238,
respectively), result in a truncated protein, and the third most
common BE alteration, H83Y (bp 247), has been shown to be
defective in biochemical analyses [32,33]. All of the non-insertion-
deletion mutations conserved the open reading frame for ARF,
suggesting specific targeting of the p16 locus for inactivation, a
phenomenon reported in other tumor types as well [34].
The p16 mutation spectrum we observed is consistent with that
mediated by reactive oxygen and nitric oxide species generated in
p16 Mutations in BE
PLoS ONE | www.plosone.org 3 November 2008 | Volume 3 | Issue 11 | e3809Figure 2. Spectrum of p16 mutations in patients with Barrett’s esophagus. A. Types of mutations observed in BE patients. Number of
events are indicated. B. Location, by base pair and frequency (number of events), of p16 mutations in BE patients.
doi:10.1371/journal.pone.0003809.g002
Figure 1. Examples of p16 mutations in Barrett’s esophagus. A) C to T transition at basepair 247. B) 1 basepair deletion at nucleotide 289.
doi:10.1371/journal.pone.0003809.g001
p16 Mutations in BE
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to acid and bile reflux and the subsequent chronic inflammation
are two potential sources of oxidative damage characteristic of
patients with BE [37–39].The higher frequency of p16 mutation at
later stages of BE and the fact that genetic alterations that have
been shown to occur later during neoplastic progression in BE,
such as p53 mutations, also display a similar mutation spectrum
[36], suggest that the ROS generated by tissue damage and
inflammation continue to act through neoplastic progression.
Oxidative damage of DNA, proteins and lipids is hypothesized
to play an etiologic role in many types of cancers, particularly
those characterized by chronic inflammation. In the esophagus,
both in vitro [40] and in vivo [41,42] studies indicate exposure to
gastroduodenal reflux results in measurable oxidative damage to
DNA. As well, p16 alterations have been observed in animal
models in response to oxidative stress [43,44], and it has been
proposed that oxidative damage may be responsible for the loss of
heterozygosity frequently observed at multiple chromosomal loci
in BE [45,46]. Oxidative stress can also induce p16 mediated
senescence (reviewed in [34]); thus, the oxidative damage induced
by gastroduodenal reflux provides both a mechanism for
generating genetic alterations as well as a selective pressure for
loss of wt p16 function.
To our knowledge, this is the largest study of p16 mutation
spectrum yet reported in a premalignant condition. The study was
based on a cohort design and all biopsies were obtained
prospectively using standardized protocols. The characteristics of
our cohort, including age, gender, and Barrett’s segment length
are comparable to studies from specialty centers [47,48]. Our
study was performed in a tertiary referral center and our research
cohort therefore has a higher percentage of patients with a
diagnosis of dysplasia than the general BE population; however,
this is unlikely to have affected the p16 mutation spectrum
reported here because we also detected p16 mutations in patients
without high-grade dysplasia, indicating p16 mutations can occur
very early during neoplastic progression. The observation that
frequency of mutation increased with histologic grade suggests
these patients may have experienced a longer or more intense
exposure to oxidative damage induced by reflux.
All of the data obtained in this study are consistent with
Knudsen’s two-hit model for inactivating tumor suppressor genes
Table 2. Mutations in p16/CDKN2a detected in patients with
Barrett’s esophagus.
Alteration* Diagnosis p14ARF status
Percent of BE
segment
172C.T
d HGD Pro to Leu 29
172C.T Metaplasia Pro to Leu 50
172C.T HGD Pro to Leu 43
172C.T IND/LGD Pro to Leu 67
172C.T HGD Pro to Leu 33
172C.T HGD Pro to Leu 100
172C.T
a,d HGD Pro to Leu No data
172C.T
b HGD Pro to Leu 33
174_175del2 IND/LGD Frameshift 100
175_221del47 IND/LGD Frameshift 25
179C.A IND/LGD No alteration 100
179_183dup5 IND/LGD Frameshift 100
182_283del102 Metaplasia deletion 100
181G.T Metaplasia Gly to Val 67
191_205del15 HGD deletion 100
198_343del146 IND/LGD deletion/frameshift 100
202G.A IND/LGD Arg to His 50
220G.A IND/LGD Arg to Gln 75
233_234del2
c IND/LGD Frameshift 43
235_245del11 IND/LGD Frameshift 100
238C.T Metaplasia Pro to Leu 100
238C.T
d HGD Pro to Leu 50
238C.T IND/LGD Pro to Leu 40
238C.T Metaplasia Pro to Leu 100
238C.T IND/LGD Pro to Leu 100
238C.T IND/LGD Pro to Leu 33
238C.T IND/LGD Pro to Leu 17
238C.T IND/LGD Pro to Leu 17
238C.T IND/LGD Pro to Leu 100
238C.T IND/LGD Pro to Leu 100
238C.T IND/LGD Pro to Leu 50
238_254del17 IND/LGD Frameshift 100
238C.T IND/LGD Pro to Leu 100
238C.T HGD Pro to Leu 25
247C.T
c IND/LGD Ala to Val 14
247C.T IND/LGD Ala to Val 50
247C.T HGD Ala to Val 100
247C.T IND/LGD Ala to Val 80
247C.T IND/LGD Ala to Val 25
247C.T HGD Ala to Val 100
262G.T IND/LGD Gly to Val 100
262G.T IND/LGD Gly to Val 25
289delC
d HGD Frameshift 33
290 T.C
b HGD No alteration 33
330 G.A IND/LGD Gly to Arg 100
323_341dup19 IND/LGD Frameshift 50
387C.A
a,d HGD Pro to Thr 100
a,b,cindicates three patients each having two distinct alterations found at
Table 3. Mutations in p16/CDKN2a detected in
esophagectomy patients.
Alteration Diagnosis p14ARF status
Percent of BE
segment
173dupC EA Frameshift NA
197A.C IND/LGD No alteration NA
329G.A HGD No alteration NA
Headings are same as in Table 2. Diagnosis is at the time of the esophagectomy.
doi:10.1371/journal.pone.0003809.t003
different levels in the esophagus.
dindicates mutation that was also found in esophagectomy specimen from the
same patient.
*Reference sequence used was NM_000077; nucleotide numbering is as found
in The CDKN2A Database[4]. Diagnosis is at baseline endoscopy.
**Indicates the percentage of the esophagus having Barrett’s epithelium that
contained the mutation.
doi:10.1371/journal.pone.0003809.t002
p16 Mutations in BE
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occurring in almost 60% of patients with BE, compared to 14.5%
with mutation. This may represent the fact that the genetic
mechanisms that result in LOH (mitotic recombination, non-
disjunction and reduplication, and/or deletion) are more common
than the development of point mutations. Alternatively, LOH
events may involve additional genes (e.g., p14ARF and p15),
leading to a greater selective advantage over clones containing
mutations.
We examined only a single biopsy every 2 cm from each
patient’s Barrett’s segment, making it possible that the frequencies
of mutation we observe are underestimates of the true value.
However, since clones with p16 mutations were observed to have
covered an average of 66% of the Barrett’s segment, it is unlikely
that many alterations were missed. However, it is possible we
missed rare mutations that occurred in exon 1 of p16. The
frequency of p16 mutation we detected is higher than previously
reported in EA or in BE found in surgical resections [11,15,30,50–
53]. Our use of a flow cytometric purification of proliferating
epithelial cells may explain this higher frequency since it eliminates
possible masking of a mutation signal by the presence of
genotypically normal stromal cells. The results from this study
provide strong evidence that alterations in p16 occur early during
neoplastic progression in patients with BE and that the
physiological consequences of chronic gastroduodenal reflux are
the likely causes of these alterations.
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